Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Iterative Health, a healthcare technology and services company partnering with physicians to advance gastrointestinal care, will present five abstracts at the European Crohn's & Colitis Organization ...

Factors linked to C difficile infection in patients with IBD include IBD activity prior to infection, shorter disease ...

Data presented at key congresses in North America and EuropeCAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...